Shots:
The US FDA has granted FTD to Birelentinib (DZD8586) for the treatment of adults with r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received ≥2L of therapy, incl. a BTK & a BCL-2 inhibitor
Designation was based on pooled P-I/II data showing 84.2% ORR & DoR rate of 83.3% at 9mos.…
